Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 399-404

  Kwan, Joanne ^a   Wah Htun, Wah ^b   Huang, Yili ^c   Ko, Wilson ^c   Kwan, Tak W ^c  

^a BOSTON UNIVERSITY   (United States)

^b LUTHERAN MEDICAL CENTER   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Chinese population; Clopidogrel resistance; Percutaneous coronary intervention; Proton pump inhibitors

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TICLOPIDINE;

AGED; ARTICLE; ASIAN; ASIAN AMERICAN; BLOOD; BLOOD CLOTTING PARAMETERS; CHINA; DRUG EFFECT; DRUG RESISTANCE; ETHNOLOGY; FEMALE; HUMAN; INSTRUMENTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; STENT; THROMBOCYTE; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ASIAN AMERICANS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PLATELETS; CHINA; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; STENTS; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 84863054558     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S22273     Document Type: Article

References (36)

1. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med. 1996;334:1084-1089.
2. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
3. Kastrai A, Koch W, Berger PB, et al. Prospective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol. 2000;36:2168-2173.
4. Grubel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
5. Price MJ, Colman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681-684.
6. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038.
7. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
8. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594-606.
9. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin Pharmacol Ther. 2011:89:65-74.
10. Lim TM, Lu PY, Meheshinder S, et al. An audit of upper gastrointestinal bleeding at Seremba Hospital. Med J Malaysia. 2003;58:522-525.
11. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res. 2007;1119:227-284.
12. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992-1000.
13. Campo G, Fileti L, Valgimigli M, Marchesini J, Scalone A, Ferrari R. Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. J Blood Med. 2010;1:61-69.
14. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopdiogreltreated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. J Am Coll Cardiol. 2010;56:134-150.
15. Simon T, Verstuyft C, Mary-Krause M, et al. For the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
16. Pare G, Mehta S, Yusuf S. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;365:1-11.
17. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;30:937-944.
18. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
19. Shuldiner AR, O'Connell JR, Gurbel PA, et al. Influence of CYP2C19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence. JAMA. 2009;302:849-858.
20. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:148. e1-148. e5.
21. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G. A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934.
22. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010;121:71-79.
23. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial. Lancet. 2010;376:1233-1243.
24. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
25. Xie HG. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes Chinese subjects than in white subjects. Clin Pharmacol Ther. 1997;62:691-692.
26. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi. Pharmacogenetics. 1997;7:59-64.
27. Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol. 2007;40:448-452.
28. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics. 1996;6:265-267.
29. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997;281:604-609.
30. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-offunction polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17:1057-1064.
31. Luo HR, Poland Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther. 2006;80:33-40.
32. Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res. 2009;124:46-51.
33. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160:506-512.
34. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70:383-392.
35. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
36. Harmsze AM, van Werkum JW, ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J. 2010;31:3046-3053.